関連する実験動画

Updated: Jun 29, 2025

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

予測可能な結合エネルギーと特異性を持つ薬物結合タンパク質のデノボ設計

Lei Lu¹, Xuxu Gou², Sophia K Tan¹

¹Department of Pharmaceutical Chemistry & Cardiovascular Research Institute, University of California, San Francisco, CA 94158, USA.

Science (New York, N.Y.)

|April 4, 2024

まとめ

計算によるタンパク質設計により高親和性小分子結合物質が作られますこの研究は,ポリ (ADP-リボース) ポリメラーゼ-1阻害剤のためのタンパク質の新しい設計を示し,優れた結合親和性と検証された相互作用を達成しました.

科学分野:

プロテイン工学とコンピューターによる薬物設計です
構造生物学と分子ダイナミクス
ファルマコフォア認識と阻害剤開発

背景:

小分子結合のためのデノボのタンパク質設計が進んでいる.
高い親和性と特異性を達成するには,しばしば設計後の広範な最適化が必要です.
薬の発見において計算手法がますます重要になってきています

研究の目的:

小分子と結合できる新種のタンパク質をコンピューターで設計する
ポリアドプリボゼポリメラーゼ-1 (PARP-1) 阻害剤に共通する薬剤を標的とする.
実験とシミュレーションによる計算設計の精度を検証する.

主な方法:

新しいタンパク質の設計に計算手法を使いました
タンパク質と薬物の相互作用を確認するためにX線結晶学を用いた.
結合メカニズムを分析するために分子ダイナミクスシミュレーションを行いました.
実験データと比較するために,結合の自由エネルギーを計算した.

主要な成果:

3つのタンパク質を成功裏に設計し,そのうちの1つは異なるPARP-1阻害剤に高親密度 (<5nMから低マイクロモラー) の結合を示した.
X線構造は設計されたタンパク質と阻害剤の間の正確な相互作用を検証しました.
束縛的自由エネルギー計算は,実験的な親和度測定と密接に一致しました.
分子ダイナミクスシミュレーションにより,結合過程における水分子の役割に関する洞察が得られました.

結論:

高親和性小分子結合タンパク質のデノボ設計は,計算的アプローチのみを使用して実現可能である.
開発された計算手順は,調整可能な結合親和性および特異性を持つタンパク質の設計を可能にします.
この研究は,標的型薬の開発のためのタンパク質工学の分野を前進させています.

さらに関連する動画

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions

Published on: January 26, 2024

関連する概念動画

Conserved Binding Sites

Conserved Binding Sites

Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Protein-Drug Binding: Determination Methods

Protein-Drug Binding: Determination Methods

Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...

The Equilibrium Binding Constant and Binding Strength

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:

Drug-Receptor Bonds

Drug-Receptor Bonds

Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...

Protein-Drug Binding: Mechanism and Kinetics

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...